Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Science 37 Hldgs Inc
(NQ:
SNCE
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Science 37 Hldgs Inc
< Previous
1
2
Next >
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
May 13, 2024
Science 37’s Virtual Site Model for Clinical Research Impresses in First-of-its-Kind FDA Inspection
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
May 09, 2024
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial
May 02, 2024
Partnership with Leading Biotech Company Enrolls 28% of Study Participants with 22x Greater Enrollment Velocity Compared to Traditional Brick-and-Mortar Clinical Trial Sites
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
April 17, 2024
New patent-protected, central recruitment leverages the Science 37 Metasite™ to accelerate enrollment and dramatically reduce site burden
From
Science 37, Inc.
Via
GlobeNewswire
SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE
February 27, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE
February 10, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
SNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Science 37 Holdings, Inc. Is Fair to Shareholders
January 29, 2024
From
Halper Sadeh LLC
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq –
January 29, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
January 29, 2024
Science 37 stockholders to receive $5.75 per share in cash
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Receives Top Honors in Everest PEAK Matrix®
December 12, 2023
Science 37 emerges as the only clinical trial site to be recognized as a Leader in Decentralized Clinical Trials
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
December 07, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023
December 05, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
November 10, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023
October 24, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 06, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List
September 20, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Recognized in the Gartner® Hype Cycle™ for Life Science Clinical Development, 2023
September 13, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan
September 12, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 to Participate in H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards
August 15, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
August 11, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 to Report Second Quarter 2023 Financial Results on August 8, 2023
July 25, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)
July 11, 2023
Science 37's Metasite to Facilitate Phase 3 Study Enrollment by Expanding Access and Maximizing Convenience for Patients
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
July 07, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
June 09, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Wins 2023 MedTech Breakthrough Award for "Best Overall Clinical Trial Platform"
May 18, 2023
Science 37's unified platform that powers the Metasite receives award for outstanding digital health and technology innovation
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Reports First Quarter 2023 Financial Results
May 15, 2023
From
Science 37, Inc.
Via
GlobeNewswire
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
May 05, 2023
From
Science 37, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.